Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.

6-minute walk test reproducible, useful in systemic sclerosis

07 Oct 2018

A recent study has demonstrated the robust reproducibility for the 6-minute walk distance (6MWD) and established the utility of the 6-minute walk test (6MWT) in examining the overall prognosis of patients with systemic sclerosis (SSc).

In total, 56 patients (aged 46±12.7 years; 38 female), with 17±10 modified Rodnan skin score (mRSS) and 1±0.8 Scleroderma Health Assessment Questionnaire (SHAQ) at first referral, were included. Overall, 277 6MWT assessments (5±3.9 6MWT per patient) were conducted over 23±22.5 months of follow-up. There were eight deaths (87.5 percent SSc-related) reported.

The 6MWD absolute value had a mean of 457±117 m, with a mean Borg dyspnoea score of 4±2.2. The 6MWD intraclass correlation coefficient was 0.996 (95 percent CI, 0.995–0.999; p<0.0001).

Multivariate linear regression analysis showed the following factors to be independently associated with a lower 6MWD: sex (R2, 0.47; p<0.0001), mRSS (R2, 0.47; p=0.008), tendon friction rub (R2, 0.47; p=0.003), SHAQ (R2, 0.47; p=0.02), muscle disability score (R2, 0.47; p=0.03), DLCO% (R2, 0.47; p=0.0008), and left ventricular ejection fraction (R2, 0.47; p=0.006).

The 6MWD at first referral independently predicted overall mortality (hazard ratio [HR], 0.99; 0.988–0.999) and SSc-related mortality (HR, 0.99; 0.988–0.999).

This observational study consecutively enrolled all patients with SSc who underwent at least two 6MWT within a minimum 3-month interval plus simultaneous routine clinical, biological and functional evaluations over 6 years. In compliance with the American Thoracic Society guidelines, each 6MWT was repeated twice to assess the reproducibility of the 6MWD, with the highest value being reported for subsequent analysis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.